Cocrystal Pharma Appoints New Director, Discloses Officer Compensation
Ticker: COCP · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $400,000, $416,000, $200,000, $60,500, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, officer-compensation
TL;DR
Cocrystal Pharma adds a new director, Dr. David S. Hong, and updates officer pay details.
AI Summary
Cocrystal Pharma, Inc. announced on October 9, 2024, a change in its Board of Directors. Specifically, Dr. David S. Hong has been appointed as a new director, effective immediately. The company also disclosed compensatory arrangements for its officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are crucial for understanding executive incentives and potential dilution.
Risk Assessment
Risk Level: medium — Board changes and compensation disclosures can impact investor confidence and future financial performance.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- Dr. David S. Hong (person) — Newly appointed director
- October 9, 2024 (date) — Effective date of director appointment
FAQ
Who is the new director appointed to Cocrystal Pharma's Board?
Dr. David S. Hong was appointed as a new director to the Board of Directors of Cocrystal Pharma, Inc.
When was the new director appointment effective?
The appointment of Dr. David S. Hong was effective as of October 9, 2024.
What other information is disclosed in this 8-K filing?
The filing also discloses compensatory arrangements of certain officers.
What is the principal executive office address for Cocrystal Pharma, Inc.?
The principal executive offices are located at 19805 N. Creek Parkway, Bothell, WA 98011.
What is the SIC code for Cocrystal Pharma, Inc.?
The Standard Industrial Classification (SIC) code for Cocrystal Pharma, Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-10-10 17:02:21
Key Financial Figures
- $400,000 — nt and Co-Chief Executive Officer, from $400,000 to $416,000. Additionally, each executi
- $416,000 — ief Executive Officer, from $400,000 to $416,000. Additionally, each executive officer r
- $200,000 — h executive officer received a bonus of $200,000 and a grant of 40,000 restricted stock
- $60,500 — Company's non-employee directors: (i) a $60,500 cash stipend for service as a director,
- $100,000 — sh stipend for service as a director, a $100,000 cash stipend for service on the Company
- $44,770 — ,109 RSUs to Dr. Roger Kornberg; (ii) a $44,770 cash stipend and 27,100 RSUs to Dr. Phi
- $82,280 — 7,100 RSUs to Dr. Philip Frost; (iii) a $82,280 cash stipend and 18,957 RSUs to Steven
- $36,300 — and 18,957 RSUs to Steven Rubin; (iv) a $36,300 cash stipend and 8,067 RSUs to Fred Has
- $54,450 — 7 RSUs to Richard Pfenniger; and (vi) a $54,450 cash stipend and 14,924 RSUs to Dr. Ant
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-040757.txt ( ) — 205KB
- cocp-20241009.xsd (EX-101.SCH) — 3KB
- cocp-20241009_lab.xml (EX-101.LAB) — 33KB
- cocp-20241009_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 10, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer